Article
DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol.
BMC cancer - 8 Nov 2024
White Cassandra, Wardill Hannah, Paul Christine, Price Timothy, Karapetis Christos, Nalder Mark, Burge Matthew E, Thomas Ann, Oldmeadow Chris, Barker Daniel, Edney Laura C, Coller Janet, Bowen Joanne, Ostroff Cheri, Cheek Bruce, Carlson Mel, Rankmore Trumaine, Nagrial Adnan, Clarke Stephen, Chantrill Lorraine, Ackland Stephen, Scott Rodney J
Abstract excerpt
BACKGROUND: Fluoropyrimidine (FP) chemotherapies are commonly prescribed for upper and lower gastrointestinal, breast and head and neck malignancies. Over 16,000 people with cancer require FP chemotherapies per annum in Australia. Between 10 and 40% patients experience grade 3-4 (≥ G3) toxicities that require hospital-based management ± intensive care admission. Approximately 1% of patients die secondary to FP...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.